GSM gold starGSM Global
中文版 · Chinese

Final PECATI Phase 2 Analysis, Reported November 13: Median Overall Survival of 40.2 Months in 43 Patients With Advanced Thymic Tumors, 53% Alive at Three Years, and Grade 3 or Higher Treatment-Related Events in 44.2%

Friday, November 13, 2026 · Health · GSM News

The final analysis of the Phase 2 PECATI trial was reported on November 13 and published in the Journal of Thoracic Oncology. Led by Jordi Remon of Gustave Roussy in France, the trial evaluated lenvatinib plus pembrolizumab in previously treated patients with advanced B3-thymoma and thymic carcinoma.

The multicenter, single-arm study enrolled 43 patients with metastatic disease who had progressed after at least one platinum-based chemotherapy regimen; 84% had thymic carcinoma and 16% had B3-thymoma. Treatment consisted of oral lenvatinib 20 mg daily plus intravenous pembrolizumab 200 mg every three weeks, for up to 35 cycles.

At a median follow-up of 24.6 months, median progression-free survival was 22.1 months, up from 14.9 months in the earlier analysis, and median overall survival was 40.2 months, with 53% of patients alive at three years. The objective response rate was 25.6%, including one complete response, and the disease control rate was 93%.

On safety, grade 3 or higher treatment-related adverse events occurred in 44.2% of patients, 27.9% discontinued at least one study drug because of treatment-related toxicity, and immune-related adverse events occurred in 39.5%. The investigators note that the small sample size and single-arm design mean the results cannot establish that the combination is superior to other treatments, and that further prospective studies are needed.

Published by GSM · USA (original Chinese edition)

Photo: Wikimedia Commons, File:2206 The Location Structure and Histology of the Thymus. Cropped.png — Author: OpenStax College. Licensing: CC BY 3.0.

Latest in Health